Stephen Mayo Buys 144,400 Shares of Allogene Therapeutics
Stephen Mayo recently purchased 144,400 shares of Allogene Therapeutics, boosting insider confidence.
Key Points
- Stephen Mayo bought 144,400 shares of Allogene Therapeutics on June 18, 2026, at an average price of $2.11.
- Shares of Allogene Therapeutics traded near $2.11 on Wednesday, with a market cap of about $724.8 million.
- Analysts maintain a positive outlook, with HC Wainwright & Co. setting a price target of $11.00.
Important disclosure: EarningsIQ is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Stephen Mayo, an insider at Allogene Therapeutics, Inc. (NasdaqGS: ALLO), purchased 144,400 shares of the company on June 18, 2026. This transaction was not planned under a Rule 10b5-1 trading plan. The stock was trading at $2.11 on Wednesday.
Insider Buying and Selling at Allogene Therapeutics, Inc.
On June 18, 2026, several insiders, including Stephen Mayo, made significant purchases of Allogene Therapeutics shares. Mayo acquired 144,400 shares, contributing to a wave of insider buying. Other insiders, such as Joshua Kazam, Elizabeth Barrett, Vicki Sato, and Deborah Messemer, also bought 95,400 shares each. These purchases were made without pre-arranged plans, indicating confidence in the company's future.
Allogene Therapeutics, Inc. Stock Up 5.5%
Shares of Allogene Therapeutics traded near $2.11 on Wednesday. The company has a market capitalization of approximately $724.8 million. It operates in the biotechnology sector, focusing on developing allogeneic T cell therapies for cancer and autoimmune diseases. The stock has a 52-week low of $0.98 and a high of $4.46. Its 50-day moving average is $2.17, while the 200-day moving average is $1.76. The company holds a strong liquidity position with a current ratio of 9.65 and a quick ratio of 9.47, though it is not profitable at present, hence no meaningful P/E ratio.
$ALLO stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on Allogene Therapeutics. On April 16, 2026, HC Wainwright & Co. maintained a 'buy' rating with a price target of $11.00. Jefferies also maintained a 'buy' rating with a target of $10.00 on April 15, 2026. Meanwhile, Bernstein and Argus Research held 'hold' ratings with a target of $3.85. The consensus among analysts is a 'buy' recommendation with a mean target price of $8.49 from 10 analyst opinions.
About Allogene Therapeutics
Allogene Therapeutics, Inc. is a biotechnology company based in South San Francisco, California. Founded in 2017, it is led by CEO Dr. David D. Chang. The company specializes in developing allogeneic T cell therapies to treat cancer and autoimmune diseases. Allogene's pipeline includes CAR T cell product candidates, such as cema-cel targeting CD19 for large B-cell lymphoma, and ALLO-316 targeting CD70 for renal cell carcinoma.
Bottom Line
Stephen Mayo's recent purchase of 144,400 shares highlights insider confidence in Allogene Therapeutics. The company's focus on innovative cancer therapies and its solid liquidity position make it a subject of interest for investors. Analysts have shown continued support with favorable price targets, reflecting optimism about its future prospects. As always, it's important to remember that insider transactions are just one piece of the investment puzzle.
Get Allogene Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ALLO, sent to your inbox. Free, and you can unsubscribe anytime.
Related Filing Alerts
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.